Abstract
The scientist who first detected APOE's role in Alzheimer's disease has now formed a company, Zinfandel Pharmaceuticals, to pursue a new target he thinks is a key contributor to AD—a mitochondrial protein called TOMM40.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
